Journal article : Review

Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma

Abstract:: Background
Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10% are refractory to first‐line treatment usually consisting of R‐CHOP chemotherapy. Of those eligible for second‐line treatment, commonly consisting of salvage chemotherapy followed by autologous stem‐cell transplantation (ASCT), around 50% experience relapse. With a median overall survival of less than six to ... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Ernst, M., Oeser, A., Besiroglu, B., Caro-Valenzuela, J., Abd El Aziz, M., Monsef, I., Borchmann, P., Estcourt, L. J., Skoetz, N., & Goldkuhle, M. (2021). Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma. Cochrane Database of Systematic Reviews, 2021(9).

MLA Style

Ernst, M., et al. “Chimeric Antigen Receptor (CAR) T‐Cell Therapy for People with Relapsed or Refractory Diffuse Large B‐Cell Lymphoma.” Cochrane Database of Systematic Reviews, vol. 2021, no. 9, Cochrane Collaboration, 2021.

Chicago Style

Ernst, M, A Oeser, B Besiroglu, J Caro-Valenzuela, M Abd El Aziz, I Monsef, P Borchmann, LJ Estcourt, N Skoetz, and M Goldkuhle. 2021. “Chimeric Antigen Receptor (CAR) T‐Cell Therapy for People with Relapsed or Refractory Diffuse Large B‐Cell Lymphoma.” Cochrane Database of Systematic Reviews 2021 (9).
Share
Print

Access Document

Files:: Ernst_et_al_2021_Chimeric_antigen_receptor.pdf

(Preview, Version of record, pdf, 1.7MB, Terms of use)

Publisher copy:: 10.1002/14651858.cd013365.pub2

Authors

+ Ernst, M More by this author

Role:: Author

+ Oeser, A More by this author

Role:: Author

+ Besiroglu, B More by this author

Role:: Author

+ Caro-Valenzuela, J More by this author

Role:: Author

+ Abd El Aziz, M More by this author

Role:: Author

More authors...

Publisher:: Cochrane Collaboration
Journal:: Cochrane Database of Systematic Reviews More from this journal
Volume:: 2021
Issue:: 9
Article number:: CD013365
Place of publication:: England
Publication date:: 2021-09-13
DOI:: 10.1002/14651858.cd013365.pub2
EISSN:: 1469-493X
Pmid:: 34515338

Language:: English
Keywords:: FFR
Subtype:: Review
Pubs id:: 1198306
Local pid:: pubs:1198306
Deposit date:: 2021-10-12

Terms of use

Copyright holder:: Cochrane Collaboration
Copyright date:: 2021
Rights statement:: Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP